Edward Pham

US Patent:

20220347263, Nov 3, 2022

Filed:

Jun 9, 2020

Appl. No.:

17/617267

Inventors:

- Stanford CA, US
Edward A. Pham - Palo Alto CA, US
Anming Xiong - Redwood City CA, US

International Classification:

A61K 38/17
A61K 38/21
A61P 31/20

Abstract:

Methods and compositions are provided for reducing virus titer and eliminating virus-infected cells from an individual.

US Patent:

20220243198, Aug 4, 2022

Filed:

Apr 8, 2022

Appl. No.:

17/716497

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/11
A61P 31/16

Abstract:

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

US Patent:

20230072073, Mar 9, 2023

Filed:

Aug 1, 2022

Appl. No.:

17/878433

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/113
A61P 31/16
A61K 45/06

Abstract:

Methods of inhibiting a respiratory virus, (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods.

US Patent:

20200239880, Jul 30, 2020

Filed:

Feb 14, 2020

Appl. No.:

16/792103

Inventors:

- Stanford CA, US
Rachel Hagey Saluti - Stanford CA, US
Edward A. Pham - Palo Alto CA, US

International Classification:

C12N 15/11
A61P 31/16

Abstract:

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

US Patent:

20160113919, Apr 28, 2016

Filed:

Oct 20, 2015

Appl. No.:

14/918404

Inventors:

- Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Rajiv Lochan Gaur - Palo Alto CA, US
Tran Van - Stanford CA, US
Gary K. Schoolnik - Stanford CA, US
Edward Pham - Stanford CA, US

International Classification:

A61K 31/4706
A61K 45/06

Abstract:

This disclosure provides a method of treating a subject infected with a mycobacteria of the complex or infected with an atypical . Aspects of the method include administering to a subject in need thereof a therapeutically effective amount of an enantiomerically pure (R)-chloroquine agent. The (R)-chloroquine agent may be an analog or derivate of chloroquine having a particular stereochemistry at the position located alpha to the amino-quinoline core of the chloroquine agent. Also provided are methods of inhibiting mycobacteria of the complex or other atypical mycobacteria in a cell. Kits and pharmaceutical compositions for practicing the subject methods are also provided.